Literature DB >> 27038539

Bilosomes in the context of oral immunization: development, challenges and opportunities.

Anshuman Shukla1, Vijay Mishra2, Prashant Kesharwani3.   

Abstract

Oral administration remains the most favored means of drug administration as far as patient compliance is concerned. For the majority of vaccines and biologics, the oral route is not a good choice because of diminished uptake of the administered dose. Vesicular carriers like liposomes and niosomes are among the potential candidates for vaccine delivery by the oral route but their instability in the gastrointestinal environment is a problem. Bilosomes represent a key advance in oral vaccine delivery because they are more resistant to disruption by gastric acid as well as enzymes. Here, we focus on different aspects of bilosomes including composition, developmental techniques, stability, transitional modifications and scale-up - emphasizing their biomedical potential in oral immunization against various diseases.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27038539     DOI: 10.1016/j.drudis.2016.03.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  17 in total

Review 1.  Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.

Authors:  Manisit Das; Leaf Huang
Journal:  J Pharmacol Exp Ther       Date:  2018-12-12       Impact factor: 4.030

2.  Gellan Gum Based Sol-to-Gel Transforming System of Natamycin Transfersomes Improves Topical Ocular Delivery.

Authors:  Karthik Yadav Janga; Akshaya Tatke; Narendar Dudhipala; Sai Prachetan Balguri; Mohamed Moustafa Ibrahim; Doaa Nabih Maria; Monica M Jablonski; Soumyajit Majumdar
Journal:  J Pharmacol Exp Ther       Date:  2019-03-14       Impact factor: 4.030

Review 3.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

4.  A novel nanogel loaded with chitosan decorated bilosomes for transdermal delivery of terbutaline sulfate: artificial neural network optimization, in vitro characterization and in vivo evaluation.

Authors:  Shahira F El Menshawe; Heba M Aboud; Mohammed H Elkomy; Rasha M Kharshoum; Amany M Abdeltwab
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

5.  Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation.

Authors:  Karthik Yadav Janga; Akshaya Tatke; Sai Prachetan Balguri; Surya P Lamichanne; Mohamed Moustafa Ibrahim; Doaa Nabih Maria; Monica M Jablonski; Soumyajit Majumdar
Journal:  Artif Cells Nanomed Biotechnol       Date:  2018-02-23       Impact factor: 5.678

6.  Piceatannol-Loaded Bilosome-Stabilized Zein Protein Exhibits Enhanced Cytostatic and Apoptotic Activities in Lung Cancer Cells.

Authors:  Nabil A Alhakamy; Giuseppe Caruso; Mohammed W Al-Rabia; Shaimaa M Badr-Eldin; Hibah M Aldawsari; Hani Z Asfour; Samah Alshehri; Sami H Alzaharani; Meshari M Alhamdan; Waleed Y Rizg; Ahmed N Allam
Journal:  Pharmaceutics       Date:  2021-04-29       Impact factor: 6.321

Review 7.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

Review 8.  Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination.

Authors:  Lei Zhang; Wendi Yang; Chaohua Hu; Qianchao Wang; Yunkun Wu
Journal:  Int J Nanomedicine       Date:  2018-05-21

Review 9.  Mucosal vaccines and technology.

Authors:  A Miquel-Clopés; E G Bentley; J P Stewart; S R Carding
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

10.  Hyaluronic acid-functionalized bilosomes for targeted delivery of tripterine to inflamed area with enhancive therapy on arthritis.

Authors:  Hailing Yang; Zhenjie Liu; Yonglong Song; Changjiang Hu
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.